M&A and BD Advisory

Licensing & Deal Strategy

Our Licensing & Deal Strategy service helps pharmaceutical and biotech companies identify, evaluate, and execute licensing opportunities. We combine AI-powered asset identification with deep commercial valuation expertise to surface the highest-value deals. From target screening to term sheet development, we support both in-licensing and out-licensing strategies.

Key Benefits

How our licensing & deal strategy service delivers value to your organization.

AI-Powered Target ID

Machine learning-driven identification of licensing targets matching your therapeutic focus and strategic gaps.

Risk-Adjusted Valuation

Comprehensive asset valuation with probability-adjusted NPV, comparable deal analysis, and scenario modeling.

Deal Structuring

Term sheet development with milestone design, royalty structures, and territory rights optimization.

Negotiation Support

Expert negotiation support with data-driven justification for valuation and deal terms.

What You Get

Comprehensive deliverables that provide actionable intelligence for your team.

Licensing target landscape with scored opportunities
Risk-adjusted asset valuation with comparable deal benchmarks
Term sheet framework with milestone and royalty structure
Negotiation playbook with value justification
Deal pipeline tracker with priority ranking
Post-deal integration roadmap

Our Process

A structured methodology that delivers results in four phases.

01

Gap Analysis

Identify portfolio gaps and strategic needs that licensing can address.

02

Target Screening

AI-powered screening of global assets matching your criteria with scoring and ranking.

03

Valuation

Detailed valuation of priority targets with comparable deal analysis and scenario modeling.

04

Deal Execution

Support term sheet development, negotiation, and deal closure.

Frequently Asked Questions

How do you identify licensing targets?

We use AI to scan global pipelines, clinical trial registries, patent databases, and conference presentations to identify assets matching your therapeutic focus, development stage, and strategic criteria.

Can you support both in-licensing and out-licensing?

Yes, we support both strategies. For in-licensing, we identify acquisition targets. For out-licensing, we identify potential partners for your assets and support deal structuring.

How do you value early-stage assets?

We use comparable deal analysis, risk-adjusted NPV, probability of success by therapeutic area, and platform technology valuation methods for early-stage assets.

Ready to Get Started?

Connect with our team to discuss how our licensing & deal strategy service can support your goals.

Schedule a Consultation